Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes, Blood, vol.106, pp.247-253, 2005. ,
Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum, Leukemia, vol.22, pp.1864-1873, 2008. ,
SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis, Leuk. Res, vol.44, pp.8-16, 2016. ,
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes, Haematologica, vol.103, pp.69-79, 2018. ,
Frequent pathway mutations of splicing machinery in myelodysplasia, Nature, vol.478, pp.64-69, 2011. ,
Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium, Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts, N. Engl. J. Med, vol.365, pp.1384-1395, 2011. ,
,
, Groupe Francophone des Myélodysplasies, Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes, Blood, vol.119, pp.3211-3218, 2012.
SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment, Nat. Commun, vol.6, p.10004, 2015. ,
Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes, Blood, vol.129, pp.484-496, 2017. ,
, SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells, vol.130, pp.881-890, 2017.
Cancer-associated SF3B1 hotspot mutations induce cryptic 3? splice site selection through use of a different branch point, Cell Rep, vol.13, pp.1033-1045, 2015. ,
Physiologic expression of Sf3b1(K700E) causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation, Cancer Cell, vol.30, pp.404-417, 2016. ,
Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage, Nat. Commun, vol.7, p.10615, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01272099
Transcriptomic characterization of SF3B1 mutation reveals its pleiotropic effects in chronic lymphocytic leukemia, Cancer Cell, vol.30, pp.750-763, 2016. ,
Impact of spliceosome mutations on RNA splicing in myelodysplasia: Dysregulated genes/pathways and clinical associations, Blood, vol.132, pp.1225-1240, 2018. ,
Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia, Nat. Commun, vol.9, p.3649, 2018. ,
Hepcidin levels and their determinants in different types of myelodysplastic syndromes, PLOS ONE, vol.6, p.23109, 2011. ,
Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1, Haematologica, vol.98, pp.420-423, 2013. ,
Inappropriate expression of hepcidin is associated with iron refractory anemia: Implications for the anemia of chronic disease, Blood, vol.100, pp.3776-3781, 2002. ,
The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation, J. Clin. Invest, vol.110, pp.1037-1044, 2002. ,
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein, Blood, vol.101, pp.2461-2463, 2003. ,
Suppression of hepcidin during anemia requires erythropoietic activity, Blood, vol.108, pp.3730-3735, 2006. ,
Cazzola; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative, Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms, Blood, vol.118, pp.6239-6246, 2011. ,
High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin, Nat. Med, vol.13, pp.1096-1101, 2007. ,
Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells, Blood, vol.114, pp.181-186, 2009. ,
Identification of erythroferrone as an erythroid regulator of iron metabolism, Nat. Genet, vol.46, pp.678-684, 2014. ,
Immunoassay for human serum erythroferrone, Blood, vol.130, pp.1243-1246, 2017. ,
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol, vol.15, p.550, 2014. ,
A chemical genetics approach for the functional assessment of novel cancer genes, Cancer Res, vol.75, pp.1949-1958, 2015. ,
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes, Haematologica, vol.104, pp.497-504, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02351432
Acquired initiating mutations in early hematopoietic cells of CLL patients, Cancer Discov, vol.4, pp.1088-1101, 2014. ,
Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes, Leukemia, vol.30, pp.2322-2331, 2016. ,
Groupe Francophone des Myélodysplasies, Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion, Blood, vol.127, pp.749-760, 2016. ,
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion, Leukemia, vol.30, pp.897-905, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01321412
Comprehensive analysis of aberrant RNA splicing in myelodysplastic syndromes, Blood, vol.124, p.826, 2014. ,
Molecular architecture of SF3b and structural consequences of its cancer-related mutations, Mol. Cell, vol.64, pp.307-319, 2016. ,
The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts, Leukemia, vol.27, pp.889-896, 2013. ,
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia, Nat. Genet, vol.44, pp.47-52, 2011. ,
A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages, Leukemia, vol.28, pp.1355-1357, 2014. ,
Metabolic function of the CTRP family of hormones, Rev. Endocr. Metab. Disord, vol.15, pp.111-123, 2014. ,
Characterization of the erythropoiesis in myelodysplasia by means of ferrokinetic studies, in vitro erythroid colony formation and soluble transferrin receptor, Leukemia, vol.12, pp.340-345, 1998. ,
The soluble transferrin receptor in dysplastic erythropoiesis in myelodysplastic syndrome, Eur. J. Haematol, vol.79, pp.8-16, 2007. ,
Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin, Haematologica, vol.95, pp.505-508, 2010. ,
Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I, Blood, vol.112, pp.5241-5244, 2008. ,
Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis, Nat. Genet, vol.34, pp.97-101, 2003. ,
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization, Science, vol.306, pp.2090-2093, 2004. ,
Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions, Leuk. Res, vol.38, pp.545-550, 2014. ,
Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with ?-thalassemia major: A longitudinal study, Blood, vol.122, pp.124-133, 2013. ,
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts, Blood, vol.126, pp.233-241, 2015. ,
Natural history of idiopathic refractory sideroblastic anemia, Blood, vol.71, pp.305-312, 1988. ,
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes, Haematologica, vol.97, pp.1364-1371, 2012. ,
Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome, J. Clin. Oncol, vol.30, pp.2134-2139, 2012. ,
Reactive oxygen species levels control NF-?B activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes, Oncotarget, vol.8, pp.105510-105524, 2017. ,
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): A multicentre, open-label phase 2 dose-finding study with long-term extension study, Lancet Oncol, vol.18, pp.1338-1347, 2017. ,
Transforming growth factor-? superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis, Nat. Med, vol.20, pp.408-414, 2014. ,
An activin receptor IIA ligand trap corrects ineffective erythropoiesis in ?-thalassemia, Nat. Med, vol.20, pp.398-407, 2014. ,
Hepcidin as a therapeutic tool to limit iron overload and improve anemia in ?-thalassemic mice, J. Clin. Invest, vol.120, pp.4466-4477, 2010. ,
Global regulation of erythroid gene expression by transcription factor GATA-1, Blood, vol.104, pp.3136-3147, 2004. ,
Proposal for a common nomenclature for sequence ions in mass spectra of peptides, Biomed. Mass Spectrom, vol.11, p.601, 1984. ,
LC-MS/MS method for hepcidin-25 measurement in human and mouse serum: Clinical and research implications in iron disorders, Clin. Chem. Lab. Med, vol.53, pp.1557-1567, 2015. ,
, INSERM on November, vol.19, 2019.
, Kannengiesser (Service de Génétique, Hôpital Bichat Paris) for providing samples
) for providing the G1E-ER4 cell line and expert comments. Funding: This study was funded by INSERM, by the Institut National du Cancer INCa PLBio 2015 (INCa_9290), by INCa and the Direction Générale de l'Offre de Soins (DGOS) of the French Ministry of Social Affairs and Health through the Programme Hospitalier de Recherche Clinique, p.4 ,
L.K. received support from ANR-16-ACHN-0002-01 and from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement no. 715491). T.G. received funding from the NIH by R01 DK 065029 (and the UCLA Center for Accelerated Innovation, under NIH grant U54HL119893, Palazzolo), INCa-DGOS_5480), and by the Site de Recherche Intégrée sur le Cancer (SIRIC) CAncer Research for PErsonalized Medicine (CARPEM) ,
recorded patient clinical data ,
,
,
performed statistical analyses and reviewed the manuscript ,
,
designed the study, analyzed the data, and supervised the work ,
are inventors on a patent application on variant ERFE. The other authors declare that they have no competing interests. Data and materials availability: RNA-seq data are available in the Gene Expression Omnibus (GEO) repository (accession number GSE132836). Material transfer agreement with H3 Biomedicine Inc. (S. Buonamici) is required to obtain synthetic full-length SF3B1 WT or mutant SF3B1 K700E cDNAs. The human erythroferrone assay is available from Intrinsic LifeSciences, wrote the manuscript. Competing interests, 2018. ,
, , 2019.
A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome, Sci. Transl. Med, vol.11, p.5467, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-02449216
, INSERM on November, vol.19, 2019.
, This article cites 60 articles, 26 of which you can access for free